Healthcare provider profile · identity verified

Nani Jane Cabrera, DO

Family Practice · FRUITLAND, ID · NPI 1730180092

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	367	93
Atorvastatin Calcium	Atorvastatin Calcium	349	90
Losartan Potassium	Losartan Potassium	234	59
Omeprazole	Omeprazole	219	59
Duloxetine Hcl	Duloxetine Hcl	217	53
Pantoprazole Sodium	Pantoprazole Sodium	189	46
Lisinopril	Lisinopril	163	50
Trazodone Hcl	Trazodone Hcl	156	43
Tramadol Hcl	Tramadol Hcl	135	34
Amlodipine Besylate	Amlodipine Besylate	133	35
Montelukast Sodium	Montelukast Sodium	130	32
Metoprolol Succinate	Metoprolol Succinate	129	39
Metformin Hcl	Metformin Hcl	119	33
Spironolactone	Spironolactone	117	29
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	107	24
Albuterol Sulfate Hfa	Albuterol Sulfate	106	29
Gabapentin	Gabapentin	106	34
Ozempic	Semaglutide	105	22
Hydrochlorothiazide	Hydrochlorothiazide	94	29
Celecoxib	Celecoxib	89	27
Furosemide	Furosemide	89	28
Fluticasone Propionate	Fluticasone Propionate	85	40
Eliquis	Apixaban	83	28
Metformin Hcl Er	Metformin Hcl	81	23
Famotidine	Famotidine	80	29
Rosuvastatin Calcium	Rosuvastatin Calcium	75	24
Venlafaxine Hcl Er	Venlafaxine Hcl	71	16
Simvastatin	Simvastatin	68	18
Metoprolol Tartrate	Metoprolol Tartrate	67	16
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	64	21
Bupropion Xl	Bupropion Hcl	62	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	62	20
Allopurinol	Allopurinol	58	20
Escitalopram Oxalate	Escitalopram Oxalate	58	19
Alendronate Sodium	Alendronate Sodium	54	14
Trulicity	Dulaglutide	54	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	54	11
Jardiance	Empagliflozin	51	11
Buspirone Hcl	Buspirone Hcl	49	suppressed
Potassium Chloride	Potassium Chloride	49	17
Mounjaro	Tirzepatide	48	13
Pravastatin Sodium	Pravastatin Sodium	48	12
Tamsulosin Hcl	Tamsulosin Hcl	48	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	47	11
Sucralfate	Sucralfate	46	13
Ropinirole Hcl	Ropinirole Hcl	45	suppressed
Meloxicam	Meloxicam	43	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	43	11
Diclofenac Sodium	Diclofenac Sodium	41	11
Oxybutynin Chloride	Oxybutynin Chloride	40	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	39	11
Sertraline Hcl	Sertraline Hcl	39	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	38	suppressed
Estradiol	Estradiol	37	12
Carvedilol	Carvedilol	36	suppressed
Tizanidine Hcl	Tizanidine Hcl	34	suppressed
Oxycodone Hcl	Oxycodone Hcl	33	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	33	suppressed
Valsartan	Valsartan	33	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	32	11
Mirtazapine	Mirtazapine	32	suppressed
Synthroid	Levothyroxine Sodium	31	suppressed
Promethazine Hcl	Promethazine Hcl	27	suppressed
Propranolol Hcl	Propranolol Hcl	26	suppressed
Warfarin Sodium	Warfarin Sodium	26	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Lorazepam	Lorazepam	25	13
Lamotrigine	Lamotrigine	24	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	23	suppressed
Fentanyl	Fentanyl	23	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	22	11
Januvia	Sitagliptin Phosphate	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Azelastine Hcl	Azelastine Hcl	21	suppressed
Ezetimibe	Ezetimibe	21	suppressed
Ibandronate Sodium	Ibandronate Sodium	21	suppressed
Rybelsus	Semaglutide	21	suppressed
Estradiol (Once Weekly)	Estradiol	20	suppressed
Prednisone	Prednisone	20	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	20	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Novolog Flexpen	Insulin Aspart	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Atenolol	Atenolol	17	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Nystatin	Nystatin	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Ondansetron Odt	Ondansetron	15	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Colchicine	Colchicine	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Spiriva Respimat	Tiotropium Bromide	14	suppressed
Azithromycin	Azithromycin	13	12
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	13	suppressed
Finasteride	Finasteride	13	suppressed
Methadone Hcl	Methadone Hcl	13	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	13	suppressed
Apidra	Insulin Glulisine	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Fluconazole	Fluconazole	12	11
Lithium Carbonate	Lithium Carbonate	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Spiriva Handihaler	Tiotropium Bromide	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Varenicline Tartrate	Varenicline Tartrate	12	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error